US 11,938,169 B2
GM-CSF for treating refractory non-tuberculous mycobacteria infections
Inge Tarnow, Hørsholm (DK); Cecilia Ganslandt, Hørsholm (DK); and Mark E. Wylam, Rochester, MN (US)
Assigned to drugrecure APS, Hørsholm (DK); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 16/755,178
Filed by DRUGRECURE APS, Hørsholm (DK); and MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, Rochester, MN (US)
PCT Filed Oct. 16, 2018, PCT No. PCT/EP2018/078214
§ 371(c)(1), (2) Date Apr. 10, 2020,
PCT Pub. No. WO2019/076883, PCT Pub. Date Apr. 25, 2019.
Claims priority of provisional application 62/572,711, filed on Oct. 16, 2017.
Claims priority of application No. 17198938 (EP), filed on Oct. 27, 2017.
Prior Publication US 2020/0237869 A1, Jul. 30, 2020
Int. Cl. A61K 38/19 (2006.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/193 (2013.01) [A61P 11/00 (2018.01); A61K 9/007 (2013.01); A61K 45/06 (2013.01)] 23 Claims
 
1. A method of treating a pulmonary non-tuberculous mycobacterium (NTM) infection in a subject having a pulmonary NTM infection refractory to antibiotic treatment, the method comprising administering to the subject via pulmonary administration an effective amount of a granulocyte-macrophage colony stimulating factor (GM-CSF) in the range of 200 μg to 400 μg once or twice daily, wherein the GM-CSF is administered to the subject every week or every alternate week for at least 6 months until a sputum sample originating from the subject shows an absence of NTM, thereby treating the subject.